American Society of Hirudotherapy

Destabilase

Lysozyme with isopeptidase activity that dissolves stabilized fibrin clots — including aged thrombi resistant to tPA.

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.Last Updated: May 26, 2026 · ASH Editorial · based on the books
  • Hementerin80 kDa
  • Hementin80 kDa
  • Hementin-Like Protein (HLP-1)80 kDa
  • Leech Collagenase70 kDa
  • Haemadipsa yanyuanensis Progranulin (Hy-PGRN)70 kDa
  • Leech Apyrase67 kDa
  • Calin65 kDa
  • Hyaluronidase60 kDa
  • Antithrombin III binding protein58 kDa
  • Collagenolytic Fibrinolysin55 kDa
  • Leech Thrombospondin-Like Protein50 kDa
  • Destabilase12.5 kDa
Molecular weight (kilodaltons) of Destabilase (highlighted) alongside other characterized leech salivary compounds. Smaller proteins/peptides generally diffuse and act faster.

Mechanistic Evidence Box

Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.
Page type
Compound profile
Evidence type
Preclinical / biochemical characterization
Evidence level
In vitro
Drug vs leech
Purified natural compound
Safety domains
Bleeding

Clinical translation limit

Destabilase's reported fibrinolytic activity in vitro and in limited animal studies does NOT establish clinical efficacy as a thrombolytic agent. No FDA-approved derivative exists; whole-leech therapy is not approved for any thromboembolic indication.

Ribbon model of one green protein chain built mostly of helices, with a few small bound molecules shown as balls and sticks.
Crystal structure of medical leech destabilase (low-salt form; Marin et al., released 2023; PDB 8BBW, X-ray diffraction). Source: PDBe, EMBL-EBI — PDB 8BBW · PDBe public data (public domain)

Molecular Profile

Category
Fibrinolytic
Evidence tier
Preclinical
Molecular weight
12,500 Da
Source species
Hirudo medicinalis
Discovered
1986 · Baskova et al.
PDB structures
6OJ9

Biological Targets

  • → isopeptide ε-(γ-Glu)-Lys bonds in cross-linked fibrin

Key Citations

  1. Baskova IP, Nikonov GI (1991), Blood Coagul Fibrinolysis · PMID 1772985
  2. Kurdyumov AS, Manuvera VA, Baskova IP, Lazarev VN (2015), BMC Biochem · PMID 26589324

External Resources

Related Fibrinolytic Compounds

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.